A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases.
pirfenidone
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
04 Jan 2021
04 Jan 2021
Historique:
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
11
2
2021
Statut:
epublish
Résumé
Fibrosis is the result of chronic inflammation and is known to pathologically occur in many organs and systems. Pirfenidone (PFD) is an anti-fibrotic known for its use in idiopathic pulmonary fibrosis (IPF). In addition to being an anti-fibrotic, it acts as an anti-inflammatory and antioxidant as well. There have been studies on PFD in other diseases, some clinical and others preclinical. We have compiled and reviewed them to highlight just how widespread PFD use could be. Among many benefits of PFD in IPF, PFD has effectively improved patients' survival in those who had an acute exacerbation of IPF and has reduced respiratory-related hospitalization, among few others. PFD also has shown an improvement in vital capacity in patients with chronic hypersensitive pneumonitis. Also, it has demonstrated anti-fibrotic effects in systemic sclerosis-associated interstitial lung disease. In other diseases outside the lungs, PFD has reversed insulin resistance and proven to be effective in non-alcoholic steatohepatitis (NASH). It has prevented blindness post-alkali injury to the eye and has proven to decrease the proliferation of mesothelioma cells, just to name a few. This review encourages further research in connection with PFD and its use in other diseases and PFD pros in IPF.
Identifiants
pubmed: 33564498
doi: 10.7759/cureus.12482
pmc: PMC7861090
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e12482Informations de copyright
Copyright © 2021, Shah et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eye (Lond). 2017 Sep;31(9):1317-1328
pubmed: 28304388
Respir Res. 2019 Jun 11;20(1):119
pubmed: 31185973
Am J Transplant. 2018 Dec;18(12):3045-3059
pubmed: 30019840
Int J Rheum Dis. 2018 Feb;21(2):477-486
pubmed: 29316328
Drug Deliv Transl Res. 2018 Oct;8(5):1114-1126
pubmed: 29858820
J Am Soc Nephrol. 2011 Jun;22(6):1144-51
pubmed: 21511828
Lab Invest. 2019 Sep;99(9):1335-1348
pubmed: 31019294
J Rheumatol. 2016 Sep;43(9):1672-9
pubmed: 27370878
Respiration. 2017;94(5):408-415
pubmed: 28898890
Hypertens Res. 2012 Jan;35(1):34-40
pubmed: 21866107
Pharmacol Rep. 2019 Oct;71(5):774-781
pubmed: 31376587
Chest. 2019 Apr;155(4):712-719
pubmed: 30472023
Mol Immunol. 2018 Jul;99:134-144
pubmed: 29783158
BMC Gastroenterol. 2014 Jul 27;14:131
pubmed: 25064094
Biochem Biophys Res Commun. 2020 Jan 15;521(3):646-651
pubmed: 31679692
Curr Med Res Opin. 2019 Jul;35(7):1187-1190
pubmed: 30612467
J Ocul Pharmacol Ther. 2017 Nov;33(9):693-703
pubmed: 28933986
Transplantation. 2009 Aug 15;88(3):330-8
pubmed: 19667934
Respir Res. 2019 Mar 12;20(1):55
pubmed: 30866942
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3061-6
pubmed: 20053983
Sci Rep. 2018 Jul 3;8(1):10070
pubmed: 29968778
Respir Med. 2019 Jul;153:44-51
pubmed: 31153107
BMC Pulm Med. 2018 Nov 23;18(1):177
pubmed: 30470213
Clin Med (Lond). 2016 Feb;16(1):42-51
pubmed: 26833513
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
Eur J Pharm Sci. 2014 Jul 16;58:13-9
pubmed: 24613900
Int J Med Sci. 2015 Oct 14;12(11):840-7
pubmed: 26640402
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):139-142
pubmed: 32476893
BMC Musculoskelet Disord. 2016 Nov 11;17(1):469
pubmed: 27835939
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761
pubmed: 28471697